lutetium has been researched along with B16 Melanoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Awad, RM; Breckpot, K; Ceuppens, H; D'Huyvetter, M; De Beck, L; de Mey, W; De Ridder, K; De Vlaeminck, Y; Devoogdt, N; Ertveldt, T; Goyvaerts, C; Keyaerts, M; Krasniqi, A; Lecocq, Q; Locy, H | 1 |
| Guo, H; Miao, Y | 1 |
| Anderson, CJ; Beaino, W; Nedrow, JR | 1 |
| Anjos, RM; Cabral, P; Cabrera, M; Fernández, M; Kovacs, L; Tassano, M; Zamboni, CB | 1 |
| Dash, A; Gamre, N; Kameswaran, M; Pandey, U; Sarma, HD; Vimalnath, KV | 1 |
| Baek, HS; Choi, SJ; Choi, SM; Hong, YD; Kim, JJ; Lim, JC | 1 |
| Hoffman, TJ; Miao, Y; Quinn, TP | 1 |
7 other study(ies) available for lutetium and B16 Melanoma
| Article | Year |
|---|---|
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.
Topics: Animals; Antigens, CD20; Cell Line, Tumor; Disease Models, Animal; Lutetium; Melanoma, Experimental; Mice; Ovalbumin; Radioisotopes; Single-Domain Antibodies | 2022 |
Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide.
Topics: alpha-MSH; Animals; Cell Line, Tumor; Coordination Complexes; Drug Delivery Systems; Heterocyclic Compounds, 1-Ring; Lactams; Lutetium; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2013 |
Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
Topics: Animals; Cell Line, Tumor; Gallium Radioisotopes; Humans; Integrin alpha4beta1; Lutetium; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Positron-Emission Tomography; Radioisotopes; Skin Neoplasms | 2015 |
Development of (177)Lu-DOTA-Dendrimer and Determination of Its Effect on Metal and Ion Levels in Tumor Tissue.
Topics: Animals; Dendrimers; Ions; Lutetium; Male; Melanoma, Experimental; Metals; Mice; Mice, Inbred C57BL; Nanostructures; Nylons; Radioisotopes; Skin Neoplasms; Succinimides | 2015 |
Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers.
Topics: Animals; Bevacizumab; Cell Line, Tumor; Humans; Immunoconjugates; Lutetium; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; U937 Cells; Vascular Endothelial Growth Factor A | 2016 |
Synthesis and biological evaluation of a novel (177)Lu-DOTA-[Gly(3)-cyclized(Dap(4), (d)-Phe(7), Asp(10))-Arg(11)]α-MSH(3-13) analogue for melanocortin-1 receptor-positive tumor targeting.
Topics: alpha-MSH; Animals; Disease Models, Animal; Drug Delivery Systems; Drug Stability; Female; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Oligopeptides; Radioisotopes; Radiopharmaceuticals; Receptor, Melanocortin, Type 1; Tissue Distribution | 2012 |
Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model.
Topics: alpha-MSH; Animals; Female; Lutetium; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Radiopharmaceuticals; Yttrium Radioisotopes | 2005 |